A B S T R A C T Clinical isolates of enterococci (Streptococcus faecalis) with high-level resistance to both streptomycin and kanamycin (minimal inhibitory concentration >2,000 ,ug/ml), and resistant to synergism with penicillin and streptomycin or kanamycin were examined for aminoglycoside-inactivating enzymes. All of the 10 strains studied had streptomycin adenylyltransferase and neomycin phosphotransferase activities; the latter enzyme phosphorylated amikacin as well as its normal substrates, such as kanamycin. Substrate profiles of the neomycin phosphotransferase activity suggested that phosphorylation occurred at the 3'-hydroxyl position, i.e., aminoglycoside 3'-phosphotransferase. A transconjugant strain, which acquired high-level aminoglycoside resistance and resistance to antibiotic synergism after mating with a resistant clinical isolate, also acquired both enzyme activities. Quantitative phosphorylation of amikacin in vitro by a sonicate of the transconjugant strain inactivated the antibiotic, as measured by bioassay, and the phosphorylated drug failed to produce synergism when combined with penicillin against a strain sensitive to penicillin-amikacin synergism.
INTRODUCTION
Enterococci are less sensitive to penicillin than other streptococci (1) . Since the demonstration by Hunter in 1947 (2) , and by Jawetz et al. in 1950 (3) that penicillin and streptomycin produce synergistic killing of enterococci, combinations of penicillin and an aminoglycoside have been used in the treatment of serious human enterococcal infections.
During the last 10-15 yr, centers in various parts of the United States (4, 5) and overseas (6) have found 25-50% of clinical enterococcal isolates resistant to high levels of streptomycin and(or) kanamycin (minimal inhibitory concentration >2,000 ,ug/ml). Enterococci with high-level aminoglycoside resistance are refractory to synergism with penicillin and that aminoglycoside (7) . Therefore, infections with such resistant organisms require treatment with penicillin and an aminoglycoside to which they are not highly resistant to produce synergism. As a result, we have been interested in studying the mechanism of this resistance to determine which aminoglycosides should be used in the treatment of enterococcal infections.
Because previous work has demonstrated that highlevel resistance and resistance to synergism were transferable by conjugation into a sensitive recipient strain (8) , we have examined a series of Streptococcus fae-calis strains for aminoglycoside-inactivating enzymes: 10 clinical isolates with high-level resistance to streptomycin and kanamycin, a transconjugant strain produced by mating a sensitive recipient with one of the resistant strains, the sensitive recipient, and 5 sensitive clinical isolates were studied. A 45-Mdalton plasmid has been identified in five resistant isolates, which was not present in strains without high-level aminoglycoside resistance; this plasmid was also found in transconjugants of the sensitive recipient strain, after they had acquired high-level aminoglycoside resistance from resistant clinical isolates (8) .
Additional experiments were designed to assess the role of enzymatic modification in the high-level aminoglycoside resistance and resistance to synergism found in clinical isolates of enterococci. To relate phosphorylation to drug resistance, amikacin was phosphorylated with a crude extract of the resistant transconjugant strain, and then used with penicillin in a synergism experiment against a strain sensitive to penicillinamikacin synergism. To evaluate the possible role of ribosomal aminoglycoside resistance, we isolated ribosomes from a sensitive and resistant strain, and measured the effect of streptomycin, kanamycin, and amikacin on protein synthesis in vitro. The, results of these studies and a discussion of the relationship between aminoglycoside-inactivating enzymes, aminoglycoside resistance, and resistance to synergism found in these strains form the basis of this report. Synergism experiments. Synergism experiments were performed according to the protocol of Moellering et al. (13) . Synergism was defined as a 100-fold or greater increase in killing at 24 h by the combination of both drugs as compared to the most effective drug (penicillin) alone. The concentration of aminoglycoside used (20 ,g/ml for amikacin and dideoxykanamycin B) was less than the minimal inhibitory concentration, and did not interfere with growth ofenterococci.
METHODS
Ribosomal studies. Cells were grown in broth, harvested in the early logarithmic growth phase, and washed twice in 1 Davies, J. E. Unpublished data. TMN buffer with 0.5 mM spermidine. They were then frozen at -700C, and disrupted after thawing by grinding with twice their wet weight of alumina (14) . An S-30 crude cell extract was prepared according to the method of Nirenberg (14) , and used in subsequent studies. Protein synthesis was assessed using ['4C]phenylalanine incorporation into trichloroacetic precipitable material with polyuridylic acid as messenger RNA in crude cell extracts (14) . Aminoglycoside inhibition of protein synthesis was measured by the reduction in counts per minute diue to addition of streptomycin, kanamycin, and amikacin (15) .
RESULTS
Aminoglycoside-inactivating enzyme assays. All of the 10 clinical isolates of enterococci with high-level resistance to streptomycin and kanamycin had streptomycin adenylyltransferase and aminoglycoside phosphotransferase 3' (neomycin phosphotransferase) activity. Neither enzyme was detected in the five sensitive clinical isolates nor in the sensitive recipient strain (Table I) . However, after mating JH2-7 with a resistant clinical isolate, the transconjugant strain JH2-7 (pDR 1) (8) acquired both adenylyltransferase and phosphotransferase activities, as well as high-level resistance to streptomycin and kanamycin, and resistance to antibiotic synergism (Table I) . Neither resistant nor sensitive clinical isolates had measurable acetyltransferase activity against streptomycin, neomycin, kanamycin, amikacin, or gentamicin.
The streptomycin adenylyltransferase activity present in resistant strains was not active against spectinomycin (Fig. 1) . No bated with a crude extract of the sensitive recipient strain JH2-7 (before mating with the resistant clinical isolate), no significant loss of activity was detected by bioassay (Table II) . Synergism studies. When used with penicillin, phosphorylated amikacin (produced as described above) did not produce synergism against JH2-7, the sensitive recipient strain, which is sensitive to penicillin-amikacin synergism (Fig. 2) . The control for this experiment, which produced synergism, was penicillin with amikacin that had been incubated with the sonicate of the sensitive recipient strain, JH2-7 (Fig. 2) . After substrate profiles had demonstrated that neither sensitive or resistant strains had enzymatic activity against dideoxykanamycin B, we studied a resistant clinical isolate, EBC-22 (pDR 1), and found that it was sensitive to penicillin-dideoxykanamycin B synergism although resistant to synergism with penicillin and kanamycin, amikacin, or streptomycin (Fig. 3) .
Ribosomal studies. Ribosomes from a resistant clinical isolate, EBC-22 (pDR 1), were compared with those from the sensitive recipient strain, JH2-7. No significant differences were observed in the inhibition of radioactive phenylalanine incorporation into polypeptides by 3 aminoglycosides (streptomycin, kanamycin, and amikacin) over a wide range of concentrations (0.1-100 ,ug/ml) (Fig. 4) .
DISCUSSION
Plasmid-mediated production of aminoglycosideinactivating enzymes has been well established among gram-negative organisms, and clearly confers resistance to clinically achievable concentrations of aminoglycosides which is transferable by conjugation (16, 17) .
More recently, aminoglycoside-inactivating enzymes have been found among gram-positive bacteria as well. Courvalin and Davies (18) have reported a 3'-neomycin phosphortransferase, which also phosphorylates amikacin, in some strains of Staphylococcus aureus. However, the strains with this enzyme activity were still susceptible to amikacin.
Among enterococci, an S. faecalis strain from Jacob and Hobbs (9) with high-level streptomycin and kanamycin resistance has been found to have streptomycin adenylyltransferase and neomycin phosphotransferase activity by others2 and by ourselves. We have now described in this paper, clinical isolates with highlevel resistance to both drugs, resistance to antibiotic synergism, and both enzyme activities which transfer together by conjugation into a sensitive recipient strain. Because both enzymes are found in transconjugant strains which contain only the 45-Mdalton plasmid transferred from resistant clinical isolates (8), we have concluded that this plasmid controls the synthesis of both enzymes. The association between high-level aminoglycoside resistance, resistance to penicillin-aminoglycoside synergism, and the presence of the two aminoglycoside-inactivating enzymes suggested, but did not prove a cause and effect relationship. The fact that phosphorylation of amikacin by a sonicate from a resistant enterococcus led to inactivation of the drug by bioassay suggested that the phosphorylated drug might also be inac- tive against the enterococcus. Ho' indicator organism used in the bioa there was a theoretical possibility t ated drug could have been active aT herefore, a synergism experirm using penicillin and phosphorylatec mine if phosphorylation of aminogl pg/ml) phosphorylated neomycin and kanamycin are unlikely to do so. The exact mechanism(s) by which aminoglycoside-inactivating enzymes produce aminoglycoside / resistance is not clear. Previous work using ribosomes CONTROL isolated from Escherichia coli has shown that adenylylated streptomycin was not capable of inhibiting in vitro protein synthesis (19) . Likewise, it has also been shown that purified (3') phosphorylated kanamycin 'CN (IOU/ml) does not inhibit ribosomal protein synthesis.' Therefore, it seems likely that (3') phosphorylated amikacin is also unable to inhibit protein synthesis.
However, recent work, especially from the laboratory of Bryan and Van Den Elzen (20) , has suggested that resistance to aminoglycosides may result from de-A+PCN N0 creased uptake across cell wall or cell membrane or decreased binding to the ribosome, as well as ribosomal resistance to the inhibition of protein synthesis. Therefore, additional studies will eventually be necessary to determine the relative importance of these several stages in enzymatically produced aminoglycoside resistance in enterococci as well as other bacteria. Previous studies of streptomycin adenylyltransferase activity in gram-negative organisms have shown that the enzyme is characteristically active against spec- 16 20 24 tinomycin, and inactive against certain blocked streptomycin derivatives such as N-methyl-dihydrostreptomycin. Because the enzyme we have studied is inacin B and kanamycin tive against spectinomycin (Fig. 1) , it seems likely cillin against clinical that adenylylation may be taking place on the streptiensitive to penicillin-dine ring at the 6 position as Suzuki et al. (21) has postuesistant to penicillin-:ykanamycin B; KM, lated in S. aureus, rather than at the 3' position as it does among gram-negative bacteria. Because we have not yet been able to obtain either N-methyl-dihydrostreptomycin, or streptidine, we are presently unable wever, because the to localize the site of adenylylation by these resistant ssay was B. globigii, enterococci. that the phosphorylBecause aminoglycosides with a 3' hydroxyl group gainst enterococcus. (neomycin, kanamycin, amikacin, ribostamycin, and ient was designed, butirosin) were phosphorylated, and those without a i amikacin, to deter-3' hydroxyl group were not (gentamicin, tobramycin, Iycosides accounted netilmicin, sisomicin, and dideoxykanamycin B), it for the observed resistance to penicillin-aminoglycoside synergism seen with amikacin, kanamycin, and other aminoglycosides susceptible to phosphorylation.
We chose amikacin because it is used more frequently today in clinical practice than either kanamycin or neomycin, and because previous work had demonstrated a 3'-phosphotransferase in clinical isolates of S. aureus which phosphorylated amikacin but did not confer amikacin resistance (18) . The results of the synergism experiment demonstrated that phosphorylated amikacin does not produce synergism with penicillin against an enterococcal strain which is sensitive to penicillin-amikacin synergism (Fig. 2) . Therefore, we have concluded that phosphorylated amikacin cannot synergize with penicillin against enterococci, and that seemed most likely that phosphorylation was occurring at the 3' hydroxyl position. The exception to this generalization was lividomycin A, which does not contain a 3' hydroxyl group, but was phosphorylated by these strains and is also phosphorylated by gram-negative organisms with 3' phosphotransferase activity (22) . Because previous studies of gram-negative organisms have shown that lividomycin A is phosphorylated at the 5' position by neomycin phosphotransferases I, and III (23) , which characteristically phosphorylate at the 3' position of neomycin, kanamycin, ribostamycin, and butirosin, but are inactive against amikacin (presumably due to steric hindrance), we assume this is also taking place in S. faecalis. Therefore, it appears that the phosphorylation of neomycin, kanamycin, and amikacin observed in these strains is most likely at the 3' position, and that the enterococcal phosphotransferase is a type III (phosphorylates ribostamycin and butirosin), i.e., aminoglycoside phosphotransferase 3' (III). Our results with dideoxykanamycin B strengthen the argument that phosphorylation is taking place at the 3' position, and that phosphorylation produces resistance to antibiotic synergism. Dideoxykanamycin B differs from kanamycin A by the absence of hydroxyl groups at both the 3' and 4' positions. Because an aminoglycoside with a hydroxyl group at the 4' position but not at the 3' position (tobramycin) is not phosphorylated by resistant strains, these results (penicillindideoxykanamycin B synergism against a resistant strain and lack of phosphotransferase activity against dideoxykanamycin B among resistant clinical isolates) are consistent with a critical role of the 3' hydroxyl group and with the hypothesis that phosphorylation at the 3' position is necessary for biologic inactivation of these drugs. However, nucleo-magnetic resonance or other similar studies will eventually be required to document the structure ofthe phosphorylated aminoglycoside.
Because previous studies in our laboratory demonstrated that a mutant enterococcal strain with highlevel streptomycin resistance contained ribosomes that were relatively insensitive to the effects of streptomycin (15), we had originally speculated that the resistance in clinical enterococcal strains might also be due, at least in part, to aminoglycoside resistant ribosomes. However, comparative study of ribosomes from a sensitive strain and a highly resistant clinical strain which contained aminoglycoside-inactivating enzymes revealed no differences in the effect of streptomycin, kanamycin, or amikacin on the inhibition of protein synthesis, and we have concluded that the aminoglycoside resistance found in these strains is not due to resistant ribosomes. However, we have examined only strains with high-level resistance to both streptomycin and kanamycin, and these results do not exclude the possibility that some strains resistant to streptomycin alone may contain resistant ribosomes.
In addition to the site of adenylylation by streptomycin adenylyltransferase in resistant enterococcal strains, several other questions remain unanswered. Although the simplest explanation of our findings is that the plasmid codes for the synthesis of two aminoglycoside-inactivating enzymes, we cannot exclude the possibility that one or both gene(s) are situated on the chromosome, and that the plasmid regulates enzyme synthesis by coding for a derepressor(s). Similarly, because neither enzyme has been purified, we cannot exclude the possibility that more than one enzyme may be involved in producing the phosphotransferase activity we have found in crude extracts of resistant cells. The data reported here also do not localize the position of aminoglycoside-inactivating enzymes in enterococci, although activity remained in the supernatant fraction after centrifugation of a sonicate for 3h at 100,000g.
Our results demonstrate that plasmid-mediated production of aminoglycoside-inactivating enzymes is responsible for high-level resistance to both streptomycin and kanamycin, and resistance to penicillinstreptomycin and penicillin-kanamycin synergism among some clinical isolates of enterococci. Streptomycin is inactivated by an adenylyltransferase; 2-deoxystreptamine aminoglycosides with a 3' hydroxyl group such as neomycin, kanamycin, and amikacin are inactivated by the phosphotransferase activity of resistant strains, and thus fail to produce synergism with penicillin. Conversely, aminoglycosides lacking a 3' hydroxy group such as gentamicin, tobramycin, netilmicin, sisomicin, and dideoxykanamycin B are not inactivated by the enzyme, and consistently produce synergism with penicillin against S. faecalis strains with or without high-level resistance to streptomycin and kanamycin.3
